Red Light Therapy Side Effects and Safety: What the Evidence Shows

The Safety Record Is Unusually Clean

Across the photobiomodulation literature — thousands of controlled trials, tens of thousands of patients — adverse events are rare, mild, and generally transient. No serious adverse events attributable to therapeutic red or near-infrared light exposure appear in the systematic reviews. That's a meaningful statement about a therapy with this volume of clinical data behind it.

The absence of serious adverse events isn't because researchers weren't looking. Cochrane reviews and meta-analyses specifically track adverse events as primary outcomes. The absence of findings in rigorous systematic reviews is informative.

That said, the safety record applies to correctly administered treatment at therapeutic doses. It doesn't apply to every scenario, and there are populations who should approach this therapy with more caution or avoid it entirely.

What the Research Says About Adverse Events

The Cochrane review on LLLT for neck pain (Chow et al.) reported that adverse events in the reviewed trials were infrequent and minor — transient redness, mild local warmth, occasional headache. None required medical intervention. This is consistent across other systematic reviews in the field.

Rare reported effects from the clinical literature:

Transient erythema (redness). A temporary increase in skin redness at the treatment site, resolving within minutes to hours. This represents normal vascular response to local warming and photobiomodulation effects on circulation.

Mild local warmth. High-irradiance panels produce heat alongside therapeutic photons. At close distances with high-power devices, this can feel uncomfortable. Not damaging at consumer irradiance levels, but worth monitoring.

Temporary exacerbation of symptoms. A small number of users report a short-term increase in pain or inflammation in the first few sessions before improvement. This may represent a transient increase in inflammatory signaling before the anti-inflammatory response takes over. It typically resolves within a few sessions.

Headache. Reported rarely in trials involving treatment near the head and neck. Mechanism is unclear — possibly related to local vascular changes.

The Real Safety Concern: Eye Exposure

This is the one area where red light therapy carries genuine risk, and it's worth being direct about it.

The retina contains photoreceptors that absorb red and near-infrared wavelengths. Unlike sunburn on skin, retinal damage from excessive light exposure is painless in real time — the retina has no pain receptors. Damage manifests later as reduced visual acuity or blind spots, and it can be permanent.

At the irradiances produced by consumer panels (50–150 mW/cm²), direct staring into the light for extended sessions creates cumulative retinal exposure above safe limits. This is not hypothetical — the concern applies to any high-intensity light source including UV lamps and high-powered LEDs.

Practical guidance:

Use the goggles that come with the panel. They're designed to block therapeutic wavelengths while remaining comfortable.
Closing your eyes is not sufficient — eyelids transmit enough red and NIR light to reach the retina.
For facial treatment, position the panel slightly above or to the side, not aimed directly at closed eyes.
Do not look directly into the panel at close range.

Near-infrared light (850nm) is completely invisible. Users treating body areas below the neck don't typically face eye exposure risk, but any panel positioned near eye level requires protection.

Medications That Increase Photosensitivity

Several medications sensitize the skin or retina to light exposure. People taking photosensitizing drugs should consult a prescribing physician before using red light therapy.

Known photosensitizers relevant to this context:

Tetracycline antibiotics (doxycycline, minocycline): Increase UV and visible light sensitivity
Fluoroquinolone antibiotics (ciprofloxacin): Photosensitizing potential
Amiodarone: Cardiac medication with significant photosensitivity profile
Certain chemotherapy agents: Multiple mechanisms of photosensitization
Psoralen compounds: Used in PUVA therapy — deliberately photosensitizing, not appropriate for additional phototherapy
St. John's Wort: Herbal supplement with documented photosensitizing effects
Thiazide diuretics: Mild photosensitizing potential

This list isn't exhaustive. If you're on any regular medication and have concerns, check with your prescriber. The interaction risk varies significantly by drug and dose.

Contraindications: Who Should Avoid or Limit Exposure

Active malignancy at or near the treatment site. This is the most consistently cited contraindication in LLLT clinical guidelines. The concern is theoretical but serious: PBM stimulates cellular metabolism and proliferation. Applied to an area with active cancer, this could in theory accelerate tumor growth. No clinical evidence confirms this in humans, but the precautionary principle applies. People with a history of cancer should discuss this with their oncologist before using red light therapy over previously affected areas.

Pregnancy. There's insufficient controlled trial data on PBM use during pregnancy to establish safety. Most clinical guidelines list pregnancy as a contraindication not because harm has been demonstrated, but because the data doesn't exist to establish safety. Conservative practice: avoid treatment over the abdomen during pregnancy.

Directly over the thyroid gland. Some clinical protocols specifically exclude the anterior neck from treatment near the thyroid. The thyroid is photosensitive, and theoretical concern exists about stimulatory effects. Avoid treating the anterior neck at high doses.

Photosensitive skin conditions. Lupus (particularly SLE with photosensitive skin), porphyria, and some forms of xeroderma pigmentosum involve heightened sensitivity to light including visible wavelengths. Dermatologist consultation before treatment is appropriate.

Epilepsy with photosensitivity. Photosensitive epilepsy involves seizure triggers from flickering or pulsed light. Most panels operate in continuous mode, but some have pulse settings. Continuous mode is generally considered safe; pulsed light modes should be avoided in this population.

Recent use of retinoids on treated skin. Topical retinoids (tretinoin, adapalene) and oral retinoids (isotretinoin) increase photosensitivity. Use caution with high-irradiance treatment over skin currently on retinoid therapy.

What Doesn't Appear in the Contraindication Lists

Metal implants, pacemakers, pins and plates. Red and NIR light does not interact with metal implants. Joint replacements, surgical hardware, and internal metal do not absorb or concentrate these wavelengths. This is a frequent question with no clinical basis for concern.

Age. No evidence suggests red light therapy is less safe in older adults. The cellular mechanisms that underlie PBM function at all ages, and the elderly are well-represented in positive clinical trials for pain and skin applications.

Dark skin tones. Melanin absorbs some wavelengths, which theoretically reduces penetration in darker skin. The clinical evidence on PBM does include diverse populations, and the therapeutic window appears sufficient across skin tones. No evidence supports differential risk.

Biphasic Dose Response: When More Becomes Less

The Arndt-Schulz curve in photobiology describes a dose-response relationship where low doses produce no effect, moderate doses produce benefit, and high doses produce inhibition. This is well-documented in cell culture studies and animal research.

At consumer device irradiances (50–150 mW/cm²), reaching the inhibitory dose range requires unusually long sessions — typically over 40 minutes at maximum irradiance. Normal 10–20 minute sessions don't reach this threshold. But it's worth knowing that treating for 2 hours thinking "more is better" could be counterproductive. The effective dose is a window, not an ascending scale.

Summary

Red light therapy, used correctly with appropriate eye protection, carries a favorable safety profile supported by thousands of trials. The meaningful risks are:

Retinal damage from unprotected direct eye exposure
Contraindication concerns for active cancer near the treatment site
Drug interactions in patients on photosensitizing medications
Theoretical concerns in pregnancy (insufficient data)

For the vast majority of healthy adults treating common conditions (skin aging, pain, recovery), the risk profile is low and the adverse event history in the clinical literature is clean. None of this eliminates the value of physician consultation for anyone with a complex medical history.

LightTherapyIQ covers the clinical evidence on light therapy devices. No manufacturer pays for editorial coverage.